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New Psychoactive Substances: A Public Health Issue 
The recreational drug scene has evolved dramatically over the last decade with the emergence 
of new psychoactive substances (NPS) supplementing rather than replacing the known drug 
repertoire. NPS are natural and synthetic recreational molecules, which mimic the effects of 
traditional drugs of abuse (TDA) (e.g. cocaine, amphetamine and ecstasy), yet they are not 
internationally controlled under the United Nations 1961 and 1971 conventions. The wide 
prevalence of NPS and complex nature inherent in NPS pose public health risks and represent 
great challenges to policy-makers, front-line staff and healthcare professionals (HCPs). 
Evidence shows that NPS have caused global problems, short and long-term health harms and 
they are “more than a one night wonder” (Chatwin et al., 2017). 
NPS are characterised by a complex life-cycle. They are initially synthesised in bulk by 
chemical companies based in China and India; shipped by air or sea to Europe; sold directly in 
the illicit drug market or cut and packaged as ‘research chemicals’, food supplements or 
branded products. These labels support the covert marketing techniques undertaken by 
clandestine chemists and circumvent international legislation. NPS are sold online or in 
headshops (EMCDDA-Europol, 2016). They first appear on the deep web targeting NPS 
wholesalers, then the surface web via professional-like websites backed up with multi-buy 
deals (Corkery et al., 2017). During the first phase, the drug is mainly purchased and consumed 
by psychonauts (explorers of mind-altering activities using new NPS), who share their 
experiences on drug fora. This is followed by a displacement or substitution of a less popular 
NPS, death or birth of a new NPS (Corkery et al., 2017). Unlike pharmaceuticals, NPS are not 
produced in line with good manufacturing practices (GMP) or any type of quality assurance or 
clinical testing. They are tested directly on the consumer. 
NPS epidemic cycles (Rose et al., 2015) evidence their prevalence among all age groups and 
defined societal sectors such as school and university students, MSM (men who have sex with 
men), heroin injectors, prisoners and music festival goers (Guirguis et al., 2017a).  Their wide 
popularity is believed to be due to their  perceived ‘legal’ status, potential for new experiences 
and desirable effects (e.g. increased libido, euphoria) wide availability, relative cheapness, and 
lack of detection (Guirguis et al., 2017b). The umbrella of NPS has recently widened (> 740 
NPS) (UNODC, 2017) to include not only newly invented drugs but re-emerging failed 
pharmaceutical patents, diverted use of prescription-only, pharmacy-only and over-the-counter 
medicines and the so-called ‘smart drugs’ (cognitive, image, mood & behaviour and sexual 
enhancers; and muscle and weight-loss drugs).  
NPS pose significant public health concerns. Their complex pharmacological profile results in 
a combination of psychoactive effects (e.g. both cocaine and MDMA-like effects) previously 
only possible through cocktails of TDA. Clinical challenges faced by HCPs include the 
different routes of administration of NPS, inconsistent content in and potency of branded 
products, unclaimed active ingredients, frequent dosing, poly-drug use, presence of complex 
mixtures (Home Office, 2014), lack of knowledge of their toxicodynamics and toxicokinetics, 
different formulations and unknown knowledge of the consequences of chronic use. On 
presentation to emergency departments users rarely know what they have taken, which reduces 
the effectiveness of subsequent clinical interventions. 
Another major challenge to HCPs is how to categorise NPS, which often leads to the adoption 
of a symptom-management approach, particularly with the lack of information via professional 
databases such as Toxbase (Gilani, 2016). Management should preferably be tailored to 
patients and supported by a multi-disciplinary approach. Regular users with problems of poly-
drug use may also suffer from a dual diagnosis i.e. an addiction problem associated with 
psychiatric disorders. Users may also suffer from secondary issues e.g. cellulitis resulting from 
injecting NPS. Available classifications such as those suggested in the NEPTUNE guidelines 
(Abdulrahim & Bowden-Jones, 2015) and the Drug Wheel (Adley, 2017) offer a great support 
to HCPs, yet a regular update is necessary to map the new NPS on the drug scene. Limitations 
also include the ability of these tools to classify NPS from their complex names e.g. 
discriminating between the opioid U-47,700 and the classical cannabinoid HU-210. Another 
challenge faced by HCPs is that NPS fall outside the drug monitoring systems run by public 
health agencies (Evans-Brown et al., 2014) and this is particularly observed when non-regular 
users, who do not consider themselves as ‘drug users’ present to sexual or mental health 
services. Poor presentation to health services is also caused by the help received from peers on 
drug fora, stigma and lack of awareness or education. 
In order to offer appropriate harm reduction advice, pharmacists and   other HCPs need to know 
the following about NPS. They should be familiar their: 1) Chemistry: different NPS categories 
may have similar substructures. Knowledge of backbones may enable their classification and 
identification. In some cases, subcategories/ subfamilies have similar substructures such as 
with SCRAs (synthetic cannabinoid receptor agonists). 2) Pharmacology: the pharmacology of 
NPS has been explored in the literature (Schifano et al., 2015). HCPs should be able to 
recognise whether an NPS is an amphetamine-like, ecstasy-like, cocaine-like or opioid-like 
because this assists in treatment decisions. However, due their often  multiple pharmacological 
effects, this makes them difficult to manage. 3) Duration of action: knowledge on the duration 
of action   is important as those with short duration of action may lead to frequent dosing,   
leading overdosing and/or fatality, and is also important in detention to avoid death by 
withdrawal. 4) Routes of administration: These includes snorting, ingesting, slamming (gay 
injecting), bombing (rectal administration), smoking, liquid inhalation or vaping and 
knowledge of these informs bioavailability. 5) The formulations available:  These include 
liquids, powders, tablets, capsules, herbs, herbal extracts and resins, herbs sprayed with 
synthetic NPS, seeds and oils. 6) Physical and psychological effects: a typical example is to 
discriminate between NPS-induced psychosis (self-limiting) and a diagnosis of schizophrenia. 
7) Legislation in the UK (TSO, 2016; Guirguis & Laurence, 2017). 8) Harm reduction advice: 
knowledge of what individuals are taking, dosage: it is important to advise users that the same 
dose of the same NPS that they purchased from the same website may have different content/ 
potency, unpredictable effects, mixing NPS with other substances can have detrimental effects 
because interactions are not known, known interactions between NPS and POMs e.g. anti-
retrovirals (Abdulrahim & Bowden-Jones, 2016; Schifano et al., 2015) and effects of NPS on 
driving and operating machinery. 
Recommendations suggest that HCPs should be proactive and respond appropriately to public 
health, social and safety risks (Gilani, 2016). This can be implemented by opportunistically 
detecting NPS use and capturing prevalence and patterns of use via detailed initial assessment 
and efficient drug history taking. It is crucial to adopt holistic approaches for prevention and 
harm reduction, counsel patients on the safe use of drugs to reduce health risks (e.g. blood-
borne infection, hepatitis C, etc.), educate and signpost them to sources of information on NPS, 
identify high-risk behaviours and share information with multidisciplinary HCPs. Research is 
needed to keep pace with the continuous emergence of NPS and to develop evidence-based 
guidelines for the management of acute and chronic NPS use. Post-marketing surveillance 
processes should enable the detection of the abuse potential of POMs (Schifano et al., 2016). 
Pharmacists should be able to identify and categorise the drugs, risk assess appropriately and 
raise awareness about high-risk NPS among users, particularly those on opioid maintenance 
treatment. At a national level, recommendations suggest that treatment providers need to offer 
new services tailored to NPS users rather than TDA users (Owen-Bowden et al., 2016). 
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